NASDAQ:APOPCELLECT BIOTECH/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CELLECT BIOTECH/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.27 +0.17 (+5.48 %) (As of 07/3/2020 10:37 AM ET) Add Compare Share Today's Range$3.13Now: $3.27▼$3.3750-Day Range$2.91MA: $3.10▼$3.2952-Week Range$0.40Now: $3.27▼$6.89Volume221,537 shsAverage Volume162,728 shsMarket Capitalization$7.32 millionP/E RatioN/ADividend YieldN/ABeta2.44 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for CELLECT BIOTECH/S. Previous Next 2.8 Community Rank Outperform VotesCELLECT BIOTECH/S has received 349 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCELLECT BIOTECH/S has received 264 “underperform” votes. (Add your “underperform” vote.)Community SentimentCELLECT BIOTECH/S has received 56.93% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CELLECT BIOTECH/S and other stocks. Vote “Outperform” if you believe APOP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APOP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCELLECT BIOTECH/S does not currently pay a dividend.Dividend GrowthCELLECT BIOTECH/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CELLECT BIOTECH/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 8.67% of the stock of CELLECT BIOTECH/S is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of CELLECT BIOTECH/S is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CELLECT BIOTECH/S is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCELLECT BIOTECH/S has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APOP Previous Symbol CUSIPN/A CIK1671502 Webwww.cellect.co Phone972-9974-1444Debt Debt-to-Equity Ratio0.03 Current Ratio5.75 Quick Ratio5.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book1.70Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,860,000.00 Net MarginsN/A Return on Equity-74.03% Return on Assets-53.71%Miscellaneous Employees28 Outstanding Shares2,240,000Market Cap$7.32 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:APOP Rates by TradingView Receive APOP News and Ratings via Email Sign-up to receive the latest news and ratings for APOP and its competitors with MarketBeat's FREE daily newsletter. CELLECT BIOTECH/S (NASDAQ:APOP) Frequently Asked Questions How has CELLECT BIOTECH/S's stock been impacted by COVID-19 (Coronavirus)? CELLECT BIOTECH/S's stock was trading at $1.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APOP stock has increased by 91.2% and is now trading at $3.27. View which stocks have been most impacted by Coronavirus. When is CELLECT BIOTECH/S's next earnings date? CELLECT BIOTECH/S is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for CELLECT BIOTECH/S. How were CELLECT BIOTECH/S's earnings last quarter? CELLECT BIOTECH/S (NASDAQ:APOP) released its quarterly earnings data on Thursday, May, 21st. The company reported ($0.22) earnings per share for the quarter. View CELLECT BIOTECH/S's earnings history. Has CELLECT BIOTECH/S been receiving favorable news coverage? News articles about APOP stock have trended negative recently, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CELLECT BIOTECH/S earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about CELLECT BIOTECH/S. Who are some of CELLECT BIOTECH/S's key competitors? Some companies that are related to CELLECT BIOTECH/S include Delcath Systems (DCTH), Neovasc (NVCN), DarioHealth (DRIO), Interpace Diagnostics Group (IDXG), Biostage (BSTG), Sintx Technologies (SINT), Endologix (ELGX), Dynatronics (DYNT), Lianluo Smart (LLIT), Avinger (AVGR), Hancock Jaffe Laboratories (HJLI), PlusTherapeuticsInc . (PSTV), Hypertension Diagnostics (HDII), Encision (ECIA) and Invivo Therapeutics (NVIV). View all competitors. What other stocks do shareholders of CELLECT BIOTECH/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other CELLECT BIOTECH/S investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Protalix Biotherapeutics (PLX), Pluristem Therapeutics (PSTI), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), NVIDIA (NVDA), REDHILL BIOPHAR/S (RDHL), Sangamo Therapeutics (SGMO) and TransEnterix (TRXC). Who are CELLECT BIOTECH/S's key executives? CELLECT BIOTECH/S's management team includes the following people: Mr. Kasbian Nuriel Chirich, Co-Founder & Exec. Chairman (Age 61)Dr. Shai Yarkoni, Co-Founder, CEO & Director (Age 61)Mr. Eyal Leibovitz, Chief Financial Officer (Age 58)Dr. Ronit Bakimer-Kleiner, Chief Devel. Officer (Age 57)Dr. Amos Ofer, VP of Operations (Age 43) What is CELLECT BIOTECH/S's stock symbol? CELLECT BIOTECH/S trades on the NASDAQ under the ticker symbol "APOP." How do I buy shares of CELLECT BIOTECH/S? Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CELLECT BIOTECH/S's stock price today? One share of APOP stock can currently be purchased for approximately $3.27. How big of a company is CELLECT BIOTECH/S? CELLECT BIOTECH/S has a market capitalization of $7.32 million. CELLECT BIOTECH/S employs 28 workers across the globe. What is CELLECT BIOTECH/S's official website? The official website for CELLECT BIOTECH/S is www.cellect.co. How can I contact CELLECT BIOTECH/S? CELLECT BIOTECH/S's mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
